HighTower Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

HighTower Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,500	Closed	-$39K	–	3702
2023 Q2	$39K	Buy	+10,500	New	+$33.7K	﹤0.01%	3189
2023 Q1	–	Sell	-32,500	Closed	-$390K	–	3594
2022 Q4	$390K	Buy	32,500 +496	+2%	+$3.86K	﹤0.01%	2297
2022 Q3	$206K	Buy	32,004 +15,004	+88%	+$121K	﹤0.01%	2587
2022 Q2	$79K	Buy	17,000 +3,000	+21%	+$16K	﹤0.01%	2838
2022 Q1	$121K	Hold	14,000	–	–	﹤0.01%	2956
2021 Q4	$199K	Sell	14,000 -14,000	-50%	-$293K	﹤0.01%	2780
2021 Q3	$616K	Sell	28,000 -1,000	-3%	-$17K	﹤0.01%	1934
2021 Q2	$389K	Buy	29,000 +5,000	+21%	+$57.2K	﹤0.01%	2195
2021 Q1	$243K	Buy	24,000 +10,500	+78%	+$86.2K	﹤0.01%	2451
2020 Q4	$57K	Buy	+13,500	New	+$43.9K	﹤0.01%	2398

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HighTower Advisors's ORMP Position: Q3 2023 in Review

HighTower Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q3 2023, closing a stake of 10,500 shares — an estimated $39K sold.

HighTower Advisors first reported a position in ORMP in Q4 2020 and held it in 10 quarters. The position peaked at $616K in Q3 2021. 56 funds tracked by Wall St. Rank hold ORMP as of Q3 2023.

HighTower Advisors reported no remaining Oramed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
HighTower Advisors sold 10,500 Oramed Pharmaceuticals shares in Q3 2023, an estimated $39K.
HighTower Advisors first reported a position in Oramed Pharmaceuticals in Q4 2020 and held it in 10 quarters.
HighTower Advisors's Oramed Pharmaceuticals position peaked at $616K in Q3 2021.
56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.